tetano
Editor, Senior Moderator
PLoS One. 2013 Dec 11;8(12):e82899. doi: 10.1371/journal.pone.0082899.
Near-infrared laser adjuvant for influenza vaccine.
Kashiwagi S1, Yuan J1, Forbes B1, Hibert ML1, Lee EL1, Whicher L1, Goudie C1, Yang Y1, Chen T1, Edelblute B1, Collette B1, Edington L1, Trussler J1, Nezivar J1, Leblanc P1, Bronson R2, Tsukada K3, Suematsu M4, Dover J5, Brauns T1, Gelfand J1, Poznansky MC1.
Author information
Abstract
Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, near-infrared (NIR) laser light given in short exposures to small areas of skin, without the use of additional chemical or biological agents, significantly increases immune responses to intradermal influenza vaccination without augmenting IgE. The NIR laser-adjuvanted vaccine confers increased protection in a murine influenza lethal challenge model as compared to unadjuvanted vaccine. We show that NIR laser treatment induces the expression of specific chemokines in the skin resulting in recruitment and activation of dendritic cells and is safe to use in both mice and humans. The NIR laser adjuvant technology provides a novel, safe, low-cost, simple-to-use, potentially broadly applicable and clinically feasible approach to enhancing vaccine efficacy as an alternative to chemical and biological adjuvants.
PMID:
24349390
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/24349390
Near-infrared laser adjuvant for influenza vaccine.
Kashiwagi S1, Yuan J1, Forbes B1, Hibert ML1, Lee EL1, Whicher L1, Goudie C1, Yang Y1, Chen T1, Edelblute B1, Collette B1, Edington L1, Trussler J1, Nezivar J1, Leblanc P1, Bronson R2, Tsukada K3, Suematsu M4, Dover J5, Brauns T1, Gelfand J1, Poznansky MC1.
Author information
Abstract
Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, near-infrared (NIR) laser light given in short exposures to small areas of skin, without the use of additional chemical or biological agents, significantly increases immune responses to intradermal influenza vaccination without augmenting IgE. The NIR laser-adjuvanted vaccine confers increased protection in a murine influenza lethal challenge model as compared to unadjuvanted vaccine. We show that NIR laser treatment induces the expression of specific chemokines in the skin resulting in recruitment and activation of dendritic cells and is safe to use in both mice and humans. The NIR laser adjuvant technology provides a novel, safe, low-cost, simple-to-use, potentially broadly applicable and clinically feasible approach to enhancing vaccine efficacy as an alternative to chemical and biological adjuvants.
PMID:
24349390
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/24349390